Literature DB >> 9890678

Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.

T Fujihara1, T Takeuchi, K Tsubota, N Kayagaki, H Yagita, K Okumura, T Abe.   

Abstract

The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO-1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behçet's syndrome and Sjögren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjögren's syndrome (primary SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjögren's syndrome (secondary SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in primary SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of primary SS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9890678     DOI: 10.1007/bf01451286

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

2.  Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.

Authors:  A Bohan; J B Peter; R L Bowman; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1977-07       Impact factor: 1.889

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

7.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

8.  gld/gld mice are unable to express a functional ligand for Fas.

Authors:  F Ramsdell; M S Seaman; R E Miller; T W Tough; M R Alderson; D H Lynch
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

9.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors:  J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

10.  The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Authors:  E Mysler; P Bini; J Drappa; P Ramos; S M Friedman; P H Krammer; K B Elkon
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  4 in total

1.  Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.

Authors:  T Otsuki; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; H Ueki; M Kusaka; S Kita; A Ueki
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Apoptosis and peripheral blood lymphocyte depletion in coeliac disease.

Authors:  A Di Sabatino; S D'Alò; D Millimaggi; R Ciccocioppo; R Parroni; G Sciarra; M G Cifone; G R Corazza
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

3.  The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.

Authors:  Aşkin Ateş; Gülay Kinikli; Murat Turgay; Murat Duman
Journal:  Clin Rheumatol       Date:  2004-05-15       Impact factor: 2.980

Review 4.  Targeting apoptosis in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-07-20       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.